Exactech Expands Total Hip Replacement Offerings with Full Market Release of Novation® Crown Cup System

Announces FDA approval of Novation® Element Stem to facilitate MIS and anterior surgical approach

GAINESVILLE, Fla. -- June 13, 2008 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the full-market release of the Novation® Crown Cup® Acetabular System, the latest component of the Novation Comprehensive Hip System.

The new system adds a titanium plasma-spray acetabular shell to Exactech’s hip offerings for total joint replacement. The system features Connexion GXL®, which is designed to minimize wear debris generation over standard polyethylene, while the titanium plasma spray enhances fixation for excellent initial and long-term stability.

The Novation Crown Cup system will be the platform for future acetabular growth, including different bearing options and fixation surfaces. In 2009, Exactech plans to launch a porous titanium version of the Crown Cup for primary and revision acetabular total hip.

Exactech CEO Bill Petty said, “With the introduction of the Crown Cup, we have continued to expand the Novation Comprehensive Hip System to meet clinical challenges faced by our surgeon customers. We recognize the need for advances in total hip arthroplasty as the population ages and an increasingly younger population undergoes hip replacement procedures.”

Exactech also has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Novation® Element™, which represents another femoral stem philosophy in the Novation Comprehensive Hip system. The geometry of this tapered wedge stem facilitates insertion in low profile incisions and surgical approaches, including specialized instrumentation designed specifically for the anterior approach.

About Exactech
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 30 markets in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm.

Investors may contact Chief Financial Officer Jody Phillips at 352-377-1140 or Julie Marshall or Frank Hawkins, Hawk Associates Inc., at 305-451-1888, e-mail: exactech@hawkassociates.com. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

PDF